Sua seleção (0)
Detalhe da pesquisa
1.
Prognostication of Molecular Relapses after Dasatinib or Nilotinib Discontinuation in Chronic Myeloid Leukemia (CML): A FI-LMC STOP 2G-TKI Study Update.
Blood;
134(Supplement_1): 30, 2019 Nov 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31724000
2.
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
N Engl J Med;
376(10): 917-927, 2017 03 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28273028
3.
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.
Blood;
132(4): 393-404, 2018 Jul 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-29567798
4.
Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients.
Clin Cancer Res;
25(22): 6606-6613, 2019 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31292142
5.
Sustained treatment-free remission in chronic myeloid leukaemia is associated with an increased frequency of innate CD8(+) T-cells.
Br J Haematol;
186(1): 54-59, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-30864168
6.
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.
Blood;
129(7): 846-854, 2017 02 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-27932374
7.
High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO.
Br J Haematol;
182(6): 807-815, 2018 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-29984825
8.
Superoxide dismutase 2 (SOD2) contributes to genetic stability of native and T315I-mutated BCR-ABL expressing leukemic cells.
Biochem Biophys Res Commun;
498(4): 715-722, 2018 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29550484
9.
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.
Blood;
127(6): 703-12, 2016 Feb 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-26603839
10.
Age-related health care disparities in multiple myeloma.
Hematol Oncol;
36(1): 224-231, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28429426
11.
Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: The experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents.
Cancer;
123(18): 3609-3616, 2017 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28497898
12.
Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study.
Cancer;
123(10): 1791-1799, 2017 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28026860
13.
Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study.
Haematologica;
102(8): 1368-1377, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28522576
14.
The Rho-ROCK pathway as a new pathological mechanism of innate immune subversion in chronic myeloid leukaemia.
J Pathol;
240(3): 262-268, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27513300
15.
Physicians' attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients.
Health Qual Life Outcomes;
15(1): 204, 2017 Oct 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-29047379
16.
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
Lancet Oncol;
17(5): 612-21, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27083332
17.
Evidence for eomesodermin-expressing innate-like CD8(+) KIR/NKG2A(+) T cells in human adults and cord blood samples.
Eur J Immunol;
45(7): 1926-33, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25903796
18.
Ponatinib and platelets a conflict in CML.
Blood;
133(14): 1520-1521, 2019 04 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30948369
19.
Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study.
Blood;
123(15): 2317-24, 2014 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-24569263
20.
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.
Blood;
123(9): 1353-60, 2014 Feb 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-24335106